Lymphoseek Approved for Diagnosing Cancer Severity
The injected agent was first approved in 2013 to help doctors identify lymph nodes associated with breast cancer or melanoma skin cancer, the agency said in a news release.
For the newly approved use, the agent was evaluated in clinical study of 85 people with squamous cell carcinoma of the lip, mouth or skin. The most common side effects noted were injection-site pain and irritation.
Lymphoseek is marketed by Navidea Biopharmaceuticals, based in Dublin, Ohio.
More information
The FDA has more about this approval.
'If you don't address demand, you don't address the problem' Police are only addressing the supply, but demand is what fuels the illicit sex trade, experts say. Newsday political reporter Bahar Ostadan has the story.
'If you don't address demand, you don't address the problem' Police are only addressing the supply, but demand is what fuels the illicit sex trade, experts say. Newsday political reporter Bahar Ostadan has the story.
